Home › Trial NCT05054725
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
- Trial IDNCT05054725
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorRevolution Medicines, Inc.
- Enrollment47
- Start date2021-12-30
- ConditionsNon-Small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.